GW Pharmaceuticals plc along with its U.S. subsidiary Greenwich Biosciences announced the publication of results from a Phase 3 study of cannabidiol oral solution (Epidiolex®) in patients with Lennox-Gastaut syndrome (LGS), a rare, severe and difficult-to-treat form of childhood-onset epilepsy. In this study, both evaluated doses of cannabidiol oral solution significantly reduced the monthly frequency of drop seizures compared to placebo in highly treatment-resistant patients when added to existing treatment.
“This publication in The New England Journal of Medicine marks another landmark for GW Pharmaceuticals with data again published by a top-tier, peer-reviewed journal. It offers further evidence for cannabidiol oral solution as a potential future treatment option for patients with this devastating condition,” said Justin Gover, GW’s Chief Executive Officer. “We are now in the latter stages of the FDA’s review of our New Drug Application and look forward to a decision from FDA in late June. If approved, we expect to make this important potential new medicine available to U.S. patients with LGS in the second half of the year.”